Psychedelics market

Shares :

The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy.  “Psychedelics are a boom business.”

Recreational: $ 8-19.2B calculated from cannabis market and comparable usage prevalence as well as demand size economics.

Medical: $ 373B + calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.



PsyKey Inc. is vertically integrated in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations, for use in its premium quality functional product lines to help improve and optimize everyday life.

Psykey Inc. is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogenic based therapeutics for the fast-evolving psychedelic market.

O/S : 209,000,000



M2Bio Sciences, Inc is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. with a research collaboration and funding agreement with the University of Pretoria, South Africa, as it relates to ongoing psilocybin magic mushroom research project. 

M2Bio Sciences, Inc. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial in Psilocybin research.

O/S : 50,000,000



Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases.  With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.

O/S : 236,790,000



COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

O/S : 35,930,000



Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness.  Through Numinus Bioscience (in alignment with licence holder Salvation Botanicals Ltd), Numinus has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline.

O/S : 157,480,000



MindMed Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering. The company’s immediate priority is to address the opioid crisis by developing a non-hallucinogenic version of the psychedelic ibogaine.

O/S : 326,130,000



Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

O/S : 80,450,000


Mind Cure Health Inc. | CSE: MCUR OTC : MCURF

Mind Cure is focused on finding new ways to treat the profound distress of a world suffering from a mental health crisis. This is a tremendous opportunity to bring a new category of psychoactive and psychedelic treatments to market.

Mind Cure’s founding team and advisors have deep and industry-specific experience in bio tech, life sciences, new product discovery, research, technology and entrepreneurship.

O/S : 92,640,000


Red Light Holland | CSE: TRIP OTC : TRUFF

Red Light Holland’s business revolves around the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

O/S : 229,100,000


Field Trip  | CSE: FTRP OTC : FTRPF

Field Trip is leading the medical and scientific re-emergence of psychedelics and psychedelic-enhanced therapies. Through Field Trip Health’s intentionally-designed, technology-empowered clinics providing psychedelic therapies, Field Trip Digital’s apps and resources scaling our protocols globally, and Field Trip Discovery.

O/S : 37,800,000


Enthrone Biomedical |  CSE : ENBI OTC : ENTBF

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.  

O/S : 40,766,648


Tryp Therapeutics Inc | CSE : TRYP

The Company is a pharmaceutical company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The Company intends to do this through the development of compounds with known activity and/or safety profiles. The Company’s lead program is designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin.

O/S : 60,302,222


Champignon Brands | CSE : SHRM OTC : SHRMF

Champignon Brands Inc.  is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries.

O/S : 79,260,000


PharmaTher IncCSE : PHRM OTC : PHRRF

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation, is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals such as ketamine and psilocybin, for FDA approval to treat neurological disorders.

O/S : 69,609,865



Core One Labs is a biotech company focused on bringing psychedelic medicine to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing.

O/S : 70,970,000


Lobe Sciences Ltd.CSE : LOBE OTC : GTSIF

Mastering the development of transformational medicines and devices as we build a growing portfolio of intellectual property to support wellness and improve mental health. We focus on clinical development of devices and the use of psychedelic medicines to treat specific indications and brain traumas.

O/S : 143,110,000


Cybin Inc.  | NEO : CYBN

Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

O/S : 2,128,295


Nova Mentis Life Science Corp.CSE : NOVA

Nova Mentis Life Science Corp. is a Canadian based biotechnology company that is focused on the emerging field of psychedelic medicine. The Company aims to become a global leader in this field by integrating the latest state-of-the-art medical and scientific technology into its drug development program. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as Autism Spectrum Disorder (ASD).

O/S : 111,137,867


Mydecine Innovations GroupCSE : MYCO OTC : MYCOF

Mydecine Innovations Group™ is a life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing. The company’s world-renowned medical and scientific advisory board is progressing a robust R&D pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.

O/S : 146,081,159


Shares :